Summit is at an exciting stage in its development with data from its modified diet Phase Ib clinical trial of SMT C1100 for Duchenne Muscular Dystrophy (DMD) due in Q3 2015. Positive data will enable the group to commence a Phase II open label trial and a larger Phase II placebo controlled trial. Ahead of this announcement we evaluate the significant potential upside of SMT C1100 as it continues its positive development. As an illustration, our intrinsic value could increase from 245p (SMT C1100 ....
